Manchester, UK, November 5 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, will take part in a panel discussion on big pharma partnering at BioCap 20121 in Manchester on November 6 2012.
Manchester, UK, October 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, has expanded its medicinal chemistry team with the appointment of an experienced pharmaceutical researcher. Dr Thorsten Nowak joins from AstraZeneca, where he worked for 16 years in drug design and project management.
Manchester, UK, September 3 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, will be presenting at ELRIG Drug Discovery 20121 on September 6 2012. The presentation, 'The application of ligand conformational preferences in drug discovery', will discuss how the tuning of conformational preferences can be used to optimise the potency of drug candidates.
Manchester and London, UK, April 16 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, and AstraZeneca announced today that they have signed a research collaboration agreement under which Conformetrix’s proprietary NMR-based technology will be applied across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.
Manchester, UK, March 7 2012 – The Board of Conformetrix Ltd, a leader in optimising drug discovery and design, has appointed Dr Sam Williams as Chief Executive Officer, it is announced today.
